LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Home・Stock List・Denali Therapeutics Inc

Denali Therapeutics Inc

Open

SectorHealthcare

19.19 0.73

Buy Sell

Overview

Share price change

24h

Current

Min

18.89

Max

19.64

Key metrics
By Trading Economics
Income	102K -128M
EPS	-0.69
Employees	503
EBITDA	-9.8M -135M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+81.36% upside

Dividends
By Dow Jones
Next Earnings	7 Aug 2026

Market Stats
By TradingEconomics
Market Cap	159M 3.1B
Previous open	18.46
Previous close	19.19

News Sentiment

By Acuity

27%

73%

69 / 346 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

13.355 / 16.44 Support & Resistance

Denali Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

14 May 2026, 22:44 UTC

Acquisitions, Mergers, Takeovers

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 May 2026, 22:27 UTC

Acquisitions, Mergers, Takeovers

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 May 2026, 22:12 UTC

Earnings

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 May 2026, 21:52 UTC

Acquisitions, Mergers, Takeovers

LVMH to Sell Marc Jacobs

15 May 2026, 00:00 UTC

Earnings

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 May 2026, 23:57 UTC

Acquisitions, Mergers, Takeovers

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 May 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 May 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 May 2026, 23:56 UTC

Market Talk

Gold Prices Rise on Strong Demand -- Market Talk

14 May 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 May 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

14 May 2026, 23:50 UTC

Market Talk

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 May 2026, 23:47 UTC

Earnings

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 May 2026, 23:47 UTC

Earnings

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 May 2026, 23:46 UTC

Earnings

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 May 2026, 23:46 UTC

Earnings

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 May 2026, 23:28 UTC

Market Talk

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 May 2026, 23:00 UTC

Market Talk

Australia's One Nation Party Leads In The Polls -- Market Talk

14 May 2026, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

14 May 2026, 22:46 UTC

Market Talk

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 May 2026, 22:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 May 2026, 22:35 UTC

Market Talk

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 May 2026, 22:11 UTC

Acquisitions, Mergers, Takeovers

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 May 2026, 22:06 UTC

Market Talk

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 May 2026, 22:04 UTC

Earnings

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 May 2026, 22:04 UTC

Earnings

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 May 2026, 22:04 UTC

Earnings

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 May 2026, 22:00 UTC

Earnings

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 May 2026, 21:55 UTC

Earnings

Nu Holdings 1Q EPS 18c >NU

14 May 2026, 21:55 UTC

Earnings

Nu Holdings 1Q Rev $4.97B >NU

Peer Comparison

Price change

Denali Therapeutics Inc Forecast

Price Target

By TipRanks

81.36% upside

12 Months Forecast

Average 35.91 USD 81.36%

High 42 USD

Low 23 USD

Based on 14 Wall Street analysts offering 12 month price targets forDenali Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Based on 14 analysts giving stock ratings to Denali Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

13.355 / 16.44Support & Resistance

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

69 / 346 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.